DIABETES

- A GLOBAL CHALLENGE

GLOOBE AB – COMMITTED TO THE HEALTH OF PRESENT AND FUTURE GENERATIONS

DIABETES - A GLOBAL CHALLENGE

GLOOBE AB – COMMITTED TO THE HEALTH OF PRESENT AND FUTURE GENERATIONS

Previous
Next
Previous
Next

GDM (gestational diabetes) as well as other metabolic disorders like T2DM, are reaching pandemic proportions in the world. No geographical area is truly safe or unaffected. Pharma medication and health care systems cannot manage the magnitude of people reaching pre-diabetes and diabetic conditions

The International Diabetes Federation (IDF), shows that there are 425 million patients with T2DM, which reflects a prevalence of 8.6% in the adult population in average, and in some areas this figure is significantly higher. Studies indicate that an important part of the treatment is related to nutrition, physical exercise and education. Adequate glycemic control significantly decreases the risk related complications and delays disease progression

It is urgent to provide convenient non-pharma treatments for diabetes and overweight overall, but in particularly in GDM which leads to long-term health effects on both mother and child and more than 50% of mothers will go on to develop type 2 diabetes (T2DM) within 5 to 10 years after delivery.

GDM affects not only the health of the mother but the condition also elevates the risk of premature birth, birth damages, excessive birth weight, infants with hypoglycemia after birth and ongoing health issues for the child. Emerging data further suggest other serious sequelae for these children (e.g. increased risk for ADHD).

Blood glucose control in humans is essential for well-being. Well controlled blood sugar reduces the risk for disease progression/pharma introduction. The number of patients having metabolic conditions is increasing and reaching epidemic proportions. The number of patients can quickly multiply as children born by diabetic mothers have an increased risk to develop metabolic disorders.

 

Gloobe aim to treat and prevent non-communicable diseases, in particular metabolic disorders, by using a novel concept based on natural nutrients with a substantially proven medical efficacy. Production of our patent pending product and the clinical use of our product will be in the form of a nutrient optimized biscuit which is largely already well scientifically substantiated. The product is related to the preload concept that is of relevance for the control of blood sugar and body weight.

The technology concept provides a new angle to the treatment and prevention of metabolic disorders, including diabetes. This group of disorders is closely linked to the combination of our modern life style and an unbalanced intake of incorrectly composed and processed food and our clear mission is to target diabetes and other conditions related to the metabolic syndrome, preferably by preventing such conditions to manifest.

GLOOBE AB PATENT PENDING TECHNOLOGY

Complexity into translational simplicity

POTENTIAL  APPLICATIONS

“The magnitude of metabolic disorders in human populations can’t be solved with pharma solutions alone” 

GLOOBE AB – WHO WE ARE

A Swedish Life Science company developing clinical therapy and products containing specific plant-based BFC’s (Bio-active Food Compounds) targeting to become 1st line non-pharma therapy preventing and intervening in Non-Communicable Diseases (NCD´s) like Gestational Diabetes Mellitus (GDM) and Type 2 Diabetes Mellitus (T2DM).

The optimized products which has entered the process and clinical validation stage, provides a novel, convenient and scientifically based solution for management of diabetes and overweight. The development of the process and product was made possible through an extensive multidisciplinary cooperation between food and medical science experts.  

It is anticipated that the convenient, IP protected clinical concept and product will become a new and important component within the daily food and nutrition intake, which may significantly improve the welfare of individuals who are either confirmed T2DM or those who are in the pre-diabetic stage of the disease.

The optimized products which now enter the process and clinical validation stage, provides a novel, convenient and scientifically based solution for management of diabetes and overweight. The development of the process and product was made possible through an extensive multidisciplinary cooperation between food and medical science experts.  

It is anticipated that the convenient, IP protected clinical concept and product will become a new and important component within the daily food and nutrition intake, which may significantly improve the welfare of individuals who are either confirmed T2DM or those who are in the pre-diabetic stage of the disease.

Our mission is to help you prevent metabolic disorders and manage your diabetes naturally

TECHINNOVATION 2018